Lee Peter J W, Bhatt Amit, Holmes Jordan, Podugu Amareshwar, Lopez Rocio, Walsh Matthew, Stevens Tyler
From the *Digestive Disease Institute, and †Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.
Pancreas. 2015 Aug;44(6):896-900. doi: 10.1097/MPA.0000000000000354.
The comparative outcomes of initial versus recurrent acute pancreatitis (AP) have not been clearly established.
The aim was to compare the clinical outcomes of those with an initial episode of AP to those with recurrent AP stratified by the number of prior episodes.
This retrospective cohort study included consecutive patients with AP admitted to the Cleveland Clinic between 2008 and 2011. The odds of severe AP, multisystem organ failure, ICU admission, new local complications, elevated blood urea nitrogen and bedside index for severity in acute pancreatitis score, systemic inflammatory response syndrome, and mortality were compared using univariable and multivariable logistic regression.
Two hundred and ninety two patients were included, of which 213 (72%) were admitted on their initial AP episode. Mortality in patients experiencing first episode was 4.7%, compared to 0% in patients with recurrent attack of pancreatitis (P = 0.047). Prior episodes of AP were found to be protective against multisystem organ failure (odds ratio, 0.14 for each prior episode; confidence interval, 0.01-0.76) and intensive care unit admission (0.24, confidence interval, 0.06-0.91), adjusting for potential confounding factors such as transfer status and obesity.
Patients presenting with recurrent AP may be at decreased risk of a clinically severe course and incur decreased mortality.
初次发作与复发性急性胰腺炎(AP)的对比结果尚未明确确立。
旨在比较初次发作AP患者与复发性AP患者的临床结局,并按既往发作次数进行分层。
这项回顾性队列研究纳入了2008年至2011年间连续入住克利夫兰诊所的AP患者。使用单变量和多变量逻辑回归比较了重症AP、多系统器官衰竭、入住重症监护病房(ICU)、新的局部并发症、血尿素氮升高以及急性胰腺炎严重程度床边指数、全身炎症反应综合征和死亡率的比值比。
共纳入292例患者,其中213例(72%)为初次发作AP时入院。初次发作患者的死亡率为4.7%,而复发性胰腺炎发作患者的死亡率为0%(P = 0.047)。在调整了诸如转运状态和肥胖等潜在混杂因素后,发现既往AP发作对多系统器官衰竭具有保护作用(每一次既往发作的比值比为0.14;置信区间为0.01 - 0.76)以及对入住重症监护病房具有保护作用(0.24,置信区间为0.06 - 0.91)。
复发性AP患者临床严重病程的风险可能降低,死亡率也会降低。